InnoCan Pharma Corporation
INNO
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.61M | 27.03M | 28.83M | 30.47M | 29.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.61M | 27.03M | 28.83M | 30.47M | 29.44M |
| Cost of Revenue | 2.68M | 3.12M | 3.33M | 3.16M | 3.25M |
| Gross Profit | 23.93M | 23.91M | 25.50M | 27.30M | 26.19M |
| SG&A Expenses | 24.25M | 24.07M | 24.12M | 25.54M | 25.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.87M | 28.28M | 28.51M | 30.01M | 30.68M |
| Operating Income | -1.26M | -1.25M | 318.00K | 454.00K | -1.25M |
| Income Before Tax | 85.00K | -1.51M | 629.00K | 2.17M | 919.00K |
| Income Tax Expenses | 426.00K | 739.00K | 937.00K | 1.21M | 1.18M |
| Earnings from Continuing Operations | -0.34 | -2.24 | -0.31 | 0.96 | -0.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -783.00K | -989.00K | -1.27M | -1.61M | -1.57M |
| Net Income | -1.12M | -3.23M | -1.58M | -649.00K | -1.83M |
| EBIT | -1.26M | -1.25M | 318.00K | 454.00K | -1.25M |
| EBITDA | -1.21M | -1.22M | 352.00K | 489.00K | -1.21M |
| EPS Basic | -0.25 | -0.72 | -0.35 | -0.15 | -0.44 |
| Normalized Basic EPS | -0.21 | -0.40 | -0.18 | -0.06 | -0.24 |
| EPS Diluted | -0.25 | -0.72 | -0.35 | -0.15 | -0.44 |
| Normalized Diluted EPS | -0.21 | -0.40 | -0.18 | -0.06 | -0.24 |
| Average Basic Shares Outstanding | 17.94M | 17.88M | 17.71M | 17.53M | 17.22M |
| Average Diluted Shares Outstanding | 17.94M | 17.88M | 17.71M | 17.53M | 17.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |